Wednesday, September 21, 2016

Mylan CEO to Shift Blame on EpiPen Pricing at Hearing

Mylan CEO Heather Bresch plans to defend the rising price of EpiPens when testifying before Congress Wednesday, sticking to the company’s effort to shift blame to health insurers and drug-benefit managers.

from WSJ.com: US Business http://ift.tt/2d8FrgL
via IFTTT

No comments:

Post a Comment